6580 Stock Overview
TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TaiRx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$39.70 |
| 52 Week High | NT$41.85 |
| 52 Week Low | NT$23.20 |
| Beta | 0.61 |
| 1 Month Change | 63.04% |
| 3 Month Change | 58.80% |
| 1 Year Change | 11.83% |
| 3 Year Change | 20.49% |
| 5 Year Change | 59.17% |
| Change since IPO | -30.39% |
Recent News & Updates
Shareholder Returns
| 6580 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 8.0% | -0.5% | 1.8% |
| 1Y | 11.8% | -22.5% | 28.5% |
Return vs Industry: 6580 exceeded the TW Biotechs industry which returned -22.5% over the past year.
Return vs Market: 6580 underperformed the TW Market which returned 28.5% over the past year.
Price Volatility
| 6580 volatility | |
|---|---|
| 6580 Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 8.2% |
| 10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 6580's share price has been volatile over the past 3 months.
Volatility Over Time: 6580's weekly volatility has increased from 8% to 14% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Chien Du-Shieng | www.trx.com.tw |
TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial; and Rexis, an add-on injection therapy that is in Phase III clinical trials to treat patients with sepsis. Its pre-clinical products comprise TRX-711 that is used to treat secondary hyperparathyroidism; TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis.
TaiRx, Inc. Fundamentals Summary
| 6580 fundamental statistics | |
|---|---|
| Market cap | NT$4.37b |
| Earnings (TTM) | -NT$212.29m |
| Revenue (TTM) | NT$5.08m |
860.9x
P/S Ratio-20.6x
P/E RatioIs 6580 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6580 income statement (TTM) | |
|---|---|
| Revenue | NT$5.08m |
| Cost of Revenue | NT$2.64m |
| Gross Profit | NT$2.44m |
| Other Expenses | NT$214.73m |
| Earnings | -NT$212.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.93 |
| Gross Margin | 47.99% |
| Net Profit Margin | -4,177.33% |
| Debt/Equity Ratio | 0% |
How did 6580 perform over the long term?
See historical performance and comparison